Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is based in Oslo, Norway.
Frequently asked questions
What sector does VISTIN PHARMA ASA NK 1 (VP4) operate in?
VISTIN PHARMA ASA NK 1 belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is VISTIN PHARMA ASA NK 1 (VP4) current stock price?
As of the latest data, VISTIN PHARMA ASA NK 1 stock price is €1.73, with a previous close of €1.70. VISTIN PHARMA ASA NK 1 gained €0.03 in the last trading session, representing a 1.47% increase.
What is VISTIN PHARMA ASA NK 1 (VP4) current market capitalization?
VISTIN PHARMA ASA NK 1 market cap is approximately 76.49 million.
What is VISTIN PHARMA ASA NK 1 (VP4) Earnings Per Share (EPS)?
The trailing EPS is €0.14.
What is VISTIN PHARMA ASA NK 1 (VP4) Price-to-Earnings (P/E) ratio?
VISTIN PHARMA ASA NK 1 current P/E ratio is 12.32.
What is VISTIN PHARMA ASA NK 1 (VP4) EBITDA?
VISTIN PHARMA ASA NK 1 EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 2.49 million.
Does VISTIN PHARMA ASA NK 1 (VP4) pay dividends?
Yes. VISTIN PHARMA ASA NK 1 pays annual dividends with an annualized yield of 0.53% and an estimated annual payout of €0.10 per share.
When is the next ex-dividend date for VISTIN PHARMA ASA NK 1 (VP4)?
The next ex-dividend date is scheduled for May 22, 2027.
When is VISTIN PHARMA ASA NK 1 (VP4) next earnings report?
VISTIN PHARMA ASA NK 1 is expected to release its next earnings report on September 30, 2026.
What is VISTIN PHARMA ASA NK 1 (VP4) beta (volatility) score?
VISTIN PHARMA ASA NK 1 has a beta of 0.578, indicating lower volatility than the overall market.
